First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback